Cencora to Support Commercial Launch of Neurotech’s Encapsulated Cell Therapy in the United States
Cencora, a global pharmaceutical solutions organization, has been selected by Neurotech Pharmaceuticals, Inc., to provide integrated distribution and commercialization services to support the launch of Neurotech’s cell therapy in the United States.
The U.S. Food and Drug Administration (FDA) recently approved the therapy for the treatment of adults with idiopathic Macular Telangiectasia type 2 (MacTel).
Cencora will serve as the exclusive specialty distributor and provide comprehensive commercialization support, including third-party logistics, specialty logistics and patient support services. Cencora will leverage its Integration Hub solution to orchestrate services and provide healthcare providers and patient services teams enhanced visibility across the treatment journey, helping to simplify the care coordination process and streamline the patient journey.
“We believe in the promise of cell and gene therapies and are committed to providing CGT developers with integrated support tailored to their needs to help accelerate speed-to-market and support product success,” said Kevin Chinn, Vice President, Cell & Gene Therapy at Cencora. “Through this partnership with Neurotech, we’ll leverage our distribution infrastructure and commercialization services to help streamline market entry, reduce potential access barriers and support secure storage and distribution, enabling efficient access to the product.”
In addition to Neurotech’s encapsulated cell therapy, the Alliance for Regenerative Medicine (ARM) estimates the FDA could issue an additional 7 to 14 CGT approvals in 2025.
As a leader in specialty pharmaceutical distribution and services, Cencora offers CGT developers support at each stage of the product lifecycle. To learn more about Cencora’s capabilities, visit: https://www.cencora.com/human-health/specialties/cell-and-gene-therapy